INLIGHTA BIOSCIENCES

Inlighta Biosciences develops patent-protected technology that develops protein-based MRI contrast agents. Inlighta’s technology could benefit clinical diagnostics, which uses MRI contrast to diagnose tumors, heart conditions, muscular-skeletal problems, and other disorders. Another relevant area is the molecular imaging market, today’s fastest-growing diagnostic field, which no MRI contrast agents are currently able to target.